| Nov 6 |
Incannex Healthcare files $150M mixed securities shelf
|
| Oct 2 |
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
|
| Sep 30 |
Incannex Healthcare GAAP EPS of -$1.15
|
| Sep 30 |
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
|
| Sep 10 |
Incannex announces strategic financing up to $60M
|
| Sep 10 |
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors
|
| Sep 9 |
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives
|
| Aug 5 |
Incannex gets FDA okay for Phase 2 study of psilocybin drug
|
| Aug 5 |
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
|
| Jul 30 |
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
|
